BNCM | DELEX Merger

Menu
Get In Touch

Our Strategy

A closer look at the strengths and growth plans designed to propel its success well into the future and drive innovation, growth, market leadership in the healthcare sector.

our vision

STRONG VISIONARY LEADERSHIP

With a proven track record of success, a strong visionary leadership team, and a strategic expansion plan that spans multiple facets of the healthcare industry, DELEX is poised to become a dominant player in the global healthcare market. As the company continues to innovate, expand, and strengthen its presence in key sectors, it remains on track to achieve its ambitious goals and deliver value to its stakeholders. The future of DELEX looks brighter than ever, and investors have a unique opportunity to be part of this dynamic journey.

STRENGTHS & GROWTH PLANS

DELEX Strengths and Expansion Plans

DELEX Pharma has built a legacy of 15 years of consistent growth, earning recognition as the third-largest national player in the hospital channel market, according to IQVIA. With over three decades of expertise in the healthcare sector, DELEX’s leadership team has played a pivotal role in driving its success and establishing its industry prominence.

Key Achievements
  1. Industry Recognition: Ranked 3rd largest in the hospital channel market in the Philippines.
  2. Sustained Growth: Fifteen years of consistent revenue and operational expansion.
  3. Leadership Expertise: Over 30 years of combined experience driving innovation and efficiency in the healthcare sector.
Implications for Investors
For BNCM Investors:

DELEX’s established track record of success ensures strong growth prospects for BNCM’s operations under its leadership.

Investors can anticipate enhanced value and market competitiveness through DELEX’s proven strategies.

For DELEX Investors:

The 15-year legacy highlights DELEX’s capability to deliver sustained results, reinforcing investor confidence.

Continued growth ensures DELEX’s leadership in the healthcare industry, unlocking further opportunities for shareholder value.

DELEX’s leadership team consists of seasoned professionals with extensive experience in the pharmaceutical and medical industries. Their entrepreneurial acumen and deep expertise, developed through collaborations with multinational healthcare giants, ensure DELEX’s continued adaptability and competitive edge in the market.

Key Strengths
  1. Expertise in Healthcare: Decades of experience managing pharmaceutical and medical device portfolios.
  2. Collaborative Success: Proven track record of partnerships with global healthcare leaders.
  3. Strategic Vision: Commitment to innovation and market responsiveness.
Implications for Investors
For BNCM Investors:

The seasoned leadership team ensures strategic realignment and growth opportunities under DELEX’s management.

Investors can expect sustainable growth through leadership-driven market innovations.

For DELEX Investors:

DELEX’s leadership continues to enhance its market position through expertise and innovation.

Investors benefit from a management team dedicated to creating long-term value.

DELEX holds a wide array of licenses from the Philippines Food and Drug Administration (FDA), enabling it to import, distribute, and sell pharmaceutical products, medical devices, cosmetics, and food items. The company’s capabilities also include operating drugstores and providing online order and delivery services, underscoring its regulatory compliance and operational excellence.

Key Licenses
  1. Pharmaceuticals: Permits for importing and distributing a wide range of therapeutic products.
  2. Medical Devices: Compliance for high-quality diagnostic and therapeutic equipment.
  3. Retail and Delivery: Licenses for physical and online pharmacy operations.
Implications for Investors
For BNCM Investors:

Regulatory compliance ensures smooth integration and expanded opportunities for BNCM.

The robust license portfolio adds operational strength to BNCM under DELEX’s management.

For DELEX Investors:

FDA licenses position DELEX as a trusted provider in the healthcare sector.

Investors gain confidence in DELEX’s ability to meet diverse market demands effectively.

DELEX’s product portfolio continues to grow, with over 30 FDA-approved hospital products and numerous medical devices. Recent launches of 11 pharmaceutical products and strategic partnerships with multinational firms showcase the company’s aggressive approach to addressing diverse therapeutic and diagnostic needs.

Key Highlights
  1. New Product Launches: Expanding offerings in key therapeutic areas.
  2. Strategic Partnerships: Collaborations with leading global medical device firms.
  3. Market Responsiveness: Addressing evolving healthcare demands through innovation.
Implications for Investors
For BNCM Investors:

DELEX’s product expansion strengthens BNCM’s operational scope and market competitiveness.

Investors can expect growth driven by innovative and in-demand offerings.

For DELEX Investors:

The diversified portfolio reinforces DELEX’s market leadership and growth trajectory.

Enhanced product lines create new revenue streams and strengthen investor confidence.

DELEX’s extensive network supplies nearly 700 hospitals and over 900 Mercury Drug branches nationwide. By leveraging strategic partnerships, DELEX is expanding its footprint to enhance market development and deliver integrated healthcare solutions that improve patient outcomes.

Key Highlights
  1. Hospital Partnerships: Serving almost 700 hospitals with high-quality healthcare products.
  2. Retail Network: Supplying over 900 Mercury Drug branches across the Philippines.
  3. Strategic Collaborations: Expanding reach through alliances with key healthcare institutions.
Implications for Investors
For BNCM Investors:

DELEX’s extensive distribution network ensures a strong foundation for BNCM’s operational growth.

Investors can expect enhanced market penetration and sustained revenue streams.

For DELEX Investors:

The robust distribution network reinforces DELEX’s leadership in the healthcare market.

Strategic partnerships drive consistent growth and strengthen shareholder confidence.

The Philippine medical device market’s rapid growth presents significant opportunities for DELEX. Strategic alliances with global leaders such as Amsino, Masimo, and Verathon enable DELEX to expand its product offerings and strengthen its position as a leading distributor of high-quality healthcare solutions.

Key Strategies
  1. Global Partnerships: Collaborations with Amsino, Masimo, Verathon, and other leaders.
  2. Innovative Solutions: Expanding portfolio with cutting-edge diagnostic and therapeutic devices.
  3. Market Leadership: Cementing DELEX’s position as a trusted distributor in the healthcare sector.
Implications for Investors
For BNCM Investors:

DELEX’s focus on medical devices enhances BNCM’s competitive advantage in the healthcare industry.

Investors benefit from diversification and potential revenue growth.

For DELEX Investors:

Strengthened partnerships position DELEX to capture market share in the growing medical device sector.

Expanded offerings ensure long-term profitability and market relevance.

Following the success of its first pharmacy branch in 2021, DELEX plans to expand its retail pharmacy business to 60 locations. Strategically located near hospitals and high-traffic areas, these stores aim to meet community needs while capitalizing on the growing demand for pharmaceutical services and products.

Key Goals
  1. Strategic Locations: Expanding in areas with high patient footfall and healthcare needs.
  2. Customer-Centric Services: Providing accessible, high-quality pharmaceutical solutions.
  3. Growth Target: Scaling operations to 60 branches by leveraging market demand.
Implications for Investors
For BNCM Investors:

DELEX’s retail expansion creates new avenues for BNCM’s growth and profitability.

Investors can expect steady returns driven by increased community engagement.

For DELEX Investors:

Expanding retail operations strengthens DELEX’s market presence and revenue streams.

Strategic growth initiatives enhance investor confidence and long-term value

DELEX is tapping into the burgeoning ePharmacy market through its online platform, offering 24/7 ordering and delivery of over-the-counter medicines, prescription drugs, and health products. This expansion caters to the growing demand for convenient and affordable digital healthcare solutions.

Key Features
  1. Online Accessibility: Customers can access medications and health products anytime.
  2. Fast Delivery: Reliable delivery services ensure timely access to healthcare needs.
  3. Customer-Centric: Focused on affordability and ease of use for patients.
Implications for Investors
For BNCM Investors:

DELEX’s ePharmacy platform opens new revenue streams for BNCM under its leadership.

The expansion aligns with growing global trends in digital healthcare.

For DELEX Investors:

The ePharmacy initiative strengthens DELEX’s position in the evolving healthcare landscape.

Investors benefit from increased customer engagement and market share.

The DELEX ICU Forum exemplifies the company’s dedication to advancing healthcare through education. What began as an in-person event has evolved into a global online platform attracting nearly 200,000 healthcare professionals to discuss critical care innovations and best practices.

Key Highlights
  1. Global Reach: Engaging healthcare professionals worldwide.
  2. Educational Impact: Promoting innovations and sharing best practices in critical care.
  3. Thought Leadership: Reinforcing DELEX’s role as a pioneer in healthcare education.
Implications for Investors
For BNCM Investors:

DELEX’s focus on education highlights its commitment to sustainable growth and community impact.

Investors can expect enhanced brand visibility and goodwill.

For DELEX Investors:

The ICU Forum strengthens DELEX’s reputation as a leader in healthcare innovation.

Increased engagement drives long-term growth and investor confidence.

In 2022, DELEX acquired JMN Brothers Pharma Limited, renowned for its expertise in women’s health and beauty. This acquisition expanded DELEX’s hospital product portfolio and enabled entry into new market segments, further diversifying its offerings.

Key Benefits
  1. Expanded Portfolio: Enhanced product offerings for hospitals and healthcare providers.
  2. New Markets: Entry into women’s health and beauty segments.
  3. Strategic Growth: Strengthened competitive position in the healthcare sector.
Implications for Investors
For BNCM Investors:

Strategic acquisitions by DELEX create new opportunities for BNCM under its management.

Diversified offerings enhance growth potential and market appeal.

For DELEX Investors:

The acquisition underscores DELEX’s commitment to market expansion and innovation.

Broader portfolios drive increased revenue and shareholder value.

DELEX’s dedication to quality is underscored by its ISO 9001:2015 re-certification. This achievement highlights the company’s adherence to international standards and its commitment to delivering exceptional products and services to customers.

Key Highlights
  1. Quality Assurance: ISO 9001:2015 certification ensures consistent and high-quality standards.
  2. Operational Excellence: Improved processes and service delivery across all divisions.
  3. Global Standards: Reinforces DELEX’s position as a trusted healthcare partner.
Implications for Investors
For BNCM Investors:

DELEX’s commitment to quality strengthens operational efficiency, driving sustainable growth.

Investors can expect consistent value creation through adherence to global standards.

For DELEX Investors:

ISO certification enhances DELEX’s credibility and competitive edge.

Improved processes result in better customer satisfaction and long-term growth.

DELEX ensures operational efficiency through its state-of-the-art SAP ERP systems and a dedicated trade sales team. This robust infrastructure supports seamless inventory management and timely delivery across its distribution network.

Key Features
  1. SAP ERP Integration: Ensures accurate inventory tracking and efficient operations.
  2. Trade Sales Team: Dedicated professionals enhance customer relationships and service.
  3. Timely Deliveries: Streamlined systems for consistent supply chain performance.
Implications for Investors
For BNCM Investors:

DELEX’s advanced infrastructure ensures seamless operational integration for BNCM.

Investors benefit from efficient distribution networks and reduced operational risks.

For DELEX Investors:

The robust system supports growth, scalability, and competitive advantage.

Efficient inventory management ensures cost optimization and higher profitability.

DELEX has received numerous awards, including “Diversity Company of the Year” and “SME Company of the Year” by the Asia CEO Awards. These accolades highlight the company’s excellence in innovation, diversity, and leadership within the healthcare industry.

Key Achievements
  1. Award Recognition: Acknowledged for excellence in diversity and innovation.
  2. Industry Leadership: Reinforced credibility as a top healthcare provider.
  3. Employee Engagement: Empowering a diverse workforce to drive innovation.
Implications for Investors
For BNCM Investors:

DELEX’s recognized leadership assures stakeholders of continued operational success.

Awards highlight growth potential and reinforce investor confidence.

For DELEX Investors:

Industry accolades enhance DELEX’s market reputation and attract global investors.

Recognition drives credibility, strengthening shareholder trust.

With the Asian pharmaceutical market projected to reach US$304.8 billion by 2029, DELEX is strategically positioned to capitalize on this growth. Its comprehensive product offerings and strong market presence provide a significant competitive advantage in this booming industry.

Key Strategies
  1. Comprehensive Portfolio: Diverse product range catering to evolving healthcare needs.
  2. Market Expertise: Decades of experience in navigating Asia’s dynamic healthcare sector.
  3. Growth Opportunities: Positioning to capture a substantial share of the expanding market.
Implications for Investors
For BNCM Investors:

DELEX’s market positioning ensures robust growth opportunities for BNCM under its leadership.

Investors can expect value from expanding market dynamics and regional dominance.

For DELEX Investors:

The booming pharmaceutical market supports DELEX’s long-term growth strategy.

Strategic alignment with market trends ensures sustained profitability and investor confidence.

In Q1 2025, DELEX will file a formal application to rename BNCM to DELEX and update its ticker symbol. This rebranding aligns with the company’s global vision and marks a new chapter in its growth journey.

Key Objectives
  1. Name Change: Officially rebranding BNCM to DELEX to reflect its integration.
  2. Ticker Symbol Update: Strengthening DELEX’s market presence and corporate identity.
  3. Strategic Alignment: Reinforcing the company’s commitment to global recognition.
Implications for Investors
For BNCM Investors:

The rebranding represents a strategic evolution that enhances BNCM’s market positioning.

Investors benefit from increased visibility and alignment with DELEX’s proven track record.

For DELEX Investors:

The updated ticker symbol and rebranding solidify DELEX’s identity in the healthcare market.

Greater recognition supports shareholder confidence and long-term growth prospects.

To support future growth, DELEX will file for Regulation A with the SEC in March 2025. This filing will open new investment opportunities and provide funding to fuel the company’s ambitious expansion plans.

Key Highlights
  1. Investment Opportunities: Attracting diverse investors through Regulation A.
  2. Growth Funding: Unlocking resources for strategic initiatives and scaling operations.
  3. Market Expansion: Strengthening DELEX’s footprint in existing and new markets.
Implications for Investors
For BNCM Investors:

Regulation A enables BNCM’s growth under DELEX’s management, ensuring increased operational funding.

Investors benefit from greater opportunities for value creation.

For DELEX Investors:

Expanded funding fuels DELEX’s long-term strategic goals.

Regulation A positions DELEX for accelerated growth and market leadership.

DELEX aims to uplist to the OTCQB market in 2025, with the long-term goal of achieving a NASDAQ listing. These plans will enhance DELEX’s corporate visibility, attract global investors, and provide access to greater capital markets.

Key Objectives
  1. OTCQB Listing: Immediate step to enhance investor confidence and visibility.
  2. NASDAQ Goals: Establishing credibility in global capital markets.
  3. Investor Benefits: Expanding opportunities for shareholder returns and market reach.
Implications for Investors
For BNCM Investors:

DELEX’s uplisting enhances BNCM’s exposure to new investor markets.

Greater access to capital supports sustainable growth initiatives.

For DELEX Investors:

Uplisting positions DELEX as a credible and scalable global player.

Expanded market access drives long-term profitability and investor trust.